LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 330

Search options

  1. Article: Myelodysplastic syndrome: Approach to diagnosis in the era of personalized medicine.

    Barone, Paul / Patel, Sanjay

    Seminars in diagnostic pathology

    2023  Volume 40, Issue 3, Page(s) 172–181

    MeSH term(s) Humans ; Precision Medicine ; Myelodysplastic Syndromes/diagnosis
    Language English
    Publishing date 2023-04-18
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 605834-6
    ISSN 1930-1111 ; 0740-2570
    ISSN (online) 1930-1111
    ISSN 0740-2570
    DOI 10.1053/j.semdp.2023.04.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Tips, Tricks, and Pearls for a Superior Patient and Surgeon Experience for Wide-awake Dupuytren Surgery.

    Barone, Natasha / Lalonde, Donald H / Brutus, Jean Paul

    Plastic and reconstructive surgery. Global open

    2024  Volume 12, Issue 2, Page(s) e5570

    Abstract: Fasciectomy for Dupuytren disease is a common procedure traditionally performed with a tourniquet under general or regional anesthesia. Since the year 2001, the wide-awake local anesthesia no tourniquet (WALANT) approach has been applied successfully to ... ...

    Abstract Fasciectomy for Dupuytren disease is a common procedure traditionally performed with a tourniquet under general or regional anesthesia. Since the year 2001, the wide-awake local anesthesia no tourniquet (WALANT) approach has been applied successfully to Dupuytren surgery, with current excellent surgeon and patient satisfaction. However, using WALANT for Dupuytren surgery may be intimidating for hand surgeons who want to begin using this method. The purpose of this article is to offer a series of tips and tricks the authors have learned after having performed hundreds of WALANT fasciectomies, to make this technique easier for surgeons and a more pleasurable experience for patients.
    Language English
    Publishing date 2024-02-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2851682-5
    ISSN 2169-7574 ; 2169-7574
    ISSN (online) 2169-7574
    ISSN 2169-7574
    DOI 10.1097/GOX.0000000000005570
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Primary cutaneous marginal zone lymphoproliferative disorder following COVID-19 vaccination.

    Stephan, Carla / Barone, Paul / Kim, Jeanyoung / Ma, Linglei

    Journal of cutaneous pathology

    2023  Volume 51, Issue 3, Page(s) 193–197

    Abstract: During the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 vaccines were administered worldwide. A number of skin reactions, including primary cutaneous T-cell lymphoproliferative disorders (LPDs) were reported following COVID-19 vaccination. We ... ...

    Abstract During the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 vaccines were administered worldwide. A number of skin reactions, including primary cutaneous T-cell lymphoproliferative disorders (LPDs) were reported following COVID-19 vaccination. We report a case of primary cutaneous marginal zone lymphoproliferative disorder (PCMZLPD) secondary to COVID-19 vaccination. A 57-year-old man presented with an erythematous nodule on his left arm at the site of vaccine inoculation following his first dose of the Moderna (mRNA-1273) vaccine a few weeks prior. The nodule continued to progress in size after the second dose. A skin biopsy specimen of the nodule showed a diffuse dermal infiltrate of small to medium-sized lymphocytes with plasma cells and histiocytes. The infiltrate was composed of CD3
    MeSH term(s) Male ; Humans ; Middle Aged ; COVID-19 Vaccines/adverse effects ; Skin Neoplasms/pathology ; COVID-19/complications ; Skin Diseases/complications ; Lymphoproliferative Disorders/etiology ; Lymphoproliferative Disorders/pathology ; Vaccination/adverse effects
    Chemical Substances COVID-19 Vaccines
    Language English
    Publishing date 2023-11-28
    Publishing country United States
    Document type Case Reports
    ZDB-ID 187078-6
    ISSN 1600-0560 ; 0303-6987
    ISSN (online) 1600-0560
    ISSN 0303-6987
    DOI 10.1111/cup.14550
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Synthesis and Magnetic Properties of the Multiferroic [C(NH

    Yananose, Kunihiro / Clark, Ewan R / Saines, Paul J / Barone, Paolo / Stroppa, Alessandro / Yu, Jaejun

    Inorganic chemistry

    2023  Volume 62, Issue 42, Page(s) 17299–17309

    Abstract: We report for the first time the synthesis of [C( ... ...

    Abstract We report for the first time the synthesis of [C(NH
    Language English
    Publishing date 2023-10-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1484438-2
    ISSN 1520-510X ; 0020-1669
    ISSN (online) 1520-510X
    ISSN 0020-1669
    DOI 10.1021/acs.inorgchem.3c02557
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: A Framework for Engaging Healthcare Professional Trainees as Continuing Education Activity Planners and Speakers.

    Bridgeman, Mary Barna / Weber, Paul / Toscani, Michael / Seyss, Carolyn / Barone, Joseph A / Gonzalez, Jimmy

    Journal of CME

    2023  Volume 12, Issue 1, Page(s) 2270279

    Abstract: Health professional education and post-graduate training programs, including residencies, fellowships, and other post-graduate training experiences, may encourage or require trainee participation in continuing education (CE) activity planning and ... ...

    Abstract Health professional education and post-graduate training programs, including residencies, fellowships, and other post-graduate training experiences, may encourage or require trainee participation in continuing education (CE) activity planning and development. Providers of CE should ensure appropriate mentorship and faculty guidance during development of the activity and provide direction on the expectations of adult learning principles (e.g. identification of an educational gap; development of measurable learning objectives; inclusion of independent, balanced, and evidenced-based content; use of active learning techniques; and incorporation of learning assessment methods). Nonetheless, there is no established best practice or approach for how CE providers should ensure trainees are prepared to serve as CE activity faculty. New practitioners provided with an opportunity to participate may be unsure of where to begin and may be hesitant to engage in this new activity. In this manuscript, authors delineate key principles to incorporate when introducing trainees to CE activity development and share outcomes associated with a comparison of trainee- vs. faculty-developed and delivered CE.
    Language English
    Publishing date 2023-10-23
    Publishing country United States
    Document type Journal Article
    ISSN 2833-8073
    ISSN (online) 2833-8073
    DOI 10.1080/28338073.2023.2270279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Online: Knowledge Base Question Answering for Space Debris Queries

    Darm, Paul / Miceli-Barone, Antonio Valerio / Cohen, Shay B. / Riccardi, Annalisa

    2023  

    Abstract: Space agencies execute complex satellite operations that need to be supported by the technical knowledge contained in their extensive information systems. Knowledge bases (KB) are an effective way of storing and accessing such information at scale. In ... ...

    Abstract Space agencies execute complex satellite operations that need to be supported by the technical knowledge contained in their extensive information systems. Knowledge bases (KB) are an effective way of storing and accessing such information at scale. In this work we present a system, developed for the European Space Agency (ESA), that can answer complex natural language queries, to support engineers in accessing the information contained in a KB that models the orbital space debris environment. Our system is based on a pipeline which first generates a sequence of basic database operations, called a %program sketch, from a natural language question, then specializes the sketch into a concrete query program with mentions of entities, attributes and relations, and finally executes the program against the database. This pipeline decomposition approach enables us to train the system by leveraging out-of-domain data and semi-synthetic data generated by GPT-3, thus reducing overfitting and shortcut learning even with limited amount of in-domain training data. Our code can be found at \url{https://github.com/PaulDrm/DISCOSQA}.

    Comment: 7 pages, ACL 2023 industry track
    Keywords Computer Science - Artificial Intelligence ; Computer Science - Computation and Language ; Computer Science - Databases ; I.2.7
    Subject code 005
    Publishing date 2023-05-31
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Investigating the anticancer potential of 4-phenylthiazole derived Ru(II) and Os(II) metalacycles.

    Getreuer, Paul / Marretta, Laura / Toyoglu, Emine / Dömötör, Orsolya / Hejl, Michaela / Prado-Roller, Alexander / Cseh, Klaudia / Legin, Anton A / Jakupec, Michael A / Barone, Giampaolo / Terenzi, Alessio / Keppler, Bernhard K / Kandioller, Wolfgang

    Dalton transactions (Cambridge, England : 2003)

    2024  Volume 53, Issue 12, Page(s) 5567–5579

    Abstract: In this contribution we report the synthesis, characterization ... ...

    Abstract In this contribution we report the synthesis, characterization and
    MeSH term(s) Humans ; Molecular Structure ; Models, Molecular ; Cell Line, Tumor ; Antineoplastic Agents/chemistry ; Cell Cycle ; Ruthenium/pharmacology ; Ruthenium/chemistry ; Coordination Complexes/chemistry
    Chemical Substances Antineoplastic Agents ; Ruthenium (7UI0TKC3U5) ; Coordination Complexes
    Language English
    Publishing date 2024-03-19
    Publishing country England
    Document type Journal Article
    ZDB-ID 1472887-4
    ISSN 1477-9234 ; 1364-5447 ; 0300-9246 ; 1477-9226
    ISSN (online) 1477-9234 ; 1364-5447
    ISSN 0300-9246 ; 1477-9226
    DOI 10.1039/d4dt00245h
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design.

    Barone, Paul / DeSimone, Robert A

    Transfusion

    2020  Volume 60, Issue 6, Page(s) 1123–1127

    Abstract: Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for ... ...

    Abstract Case series studying convalescent plasma use in the treatment of COVID-19 have been promising, but additional, high-quality studies are needed to determine the efficacy of the treatment when applied for prophylaxis, for early phases of illness, and for severe illness. Previous studies of convalescent plasma in treating other viral diseases have identified factors to consider when designing treatment protocols, including timing of administration relative to onset of illness, timing of donation relative to resolution of symptoms, severity of illness of the donor, pretransfusion serology of the recipient, and antibody titers of the donor. There are many clinical trials studying treatment of, and prophylaxis against, COVID-19 using convalescent plasma. In addition to clinical trials, the FDA also allows treatment through two other pathways: the "Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19" protocol, and emergency investigational new drug applications. The FDA also provides criteria for donation of convalescent plasma.
    MeSH term(s) Antibodies, Viral/blood ; Betacoronavirus/immunology ; Blood Component Transfusion/methods ; COVID-19 ; Clinical Trials as Topic/methods ; Convalescence ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Humans ; Pandemics ; Plasma/immunology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; Research Design ; SARS-CoV-2
    Chemical Substances Antibodies, Viral
    Keywords covid19
    Language English
    Publishing date 2020-05-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.15843
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Age Demographics of Subjects Enrolled in Global, Interventional Phase 3 Melanoma Clinical Trials.

    Shah, Reema / Patel, Nil / Patel, Yasha / Toscani, Michael / Barone, Joseph / Weber, Paul F

    Therapeutic innovation & regulatory science

    2022  Volume 56, Issue 2, Page(s) 184–190

    Abstract: Background: Melanoma is a skin cancer with a rising worldwide incidence of just over 280,000 individuals with the greatest burden of illness in European, New Zealander, and Australian populations. Patients are diagnosed with melanoma with the mean and ... ...

    Abstract Background: Melanoma is a skin cancer with a rising worldwide incidence of just over 280,000 individuals with the greatest burden of illness in European, New Zealander, and Australian populations. Patients are diagnosed with melanoma with the mean and median ages being 65 and 59 years old, respectively. Phase 3 trials not only provide a wide representation of the target population but also study the efficacy for a certain intervention.
    Objective: The objective of this literature review is to analyze patient demographics of phase 3 trials for melanoma and identify if there is a true disparity between the clinical trial age demographics and the natural epidemiological age demographics.
    Data sources: The authors conducted a search on clinicaltrials.gov, a publicly available resource that lists clinical trials and their data. The reported mean and median ages for each trial were extracted after determining if each trial meets our inclusion criteria. Weighted mean and median ages were calculated using an online calculator. Data from 35 trials were evaluated with 30 trials reporting a weighted mean age of 55.85 years and 5 trials reporting a weighted median age of 55.14 years.
    Conclusion: Based on the results, melanoma clinical trials enroll patients who are younger than the epidemiological mean and median ages. Due to this underrepresentation of the elderly patients with melanoma, clinical trials may provide limited application for the use of their results.
    MeSH term(s) Aged ; Australia ; Demography ; Humans ; Melanoma/epidemiology ; Middle Aged ; Skin Neoplasms/epidemiology
    Language English
    Publishing date 2022-01-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2708397-4
    ISSN 2168-4804 ; 2168-4790
    ISSN (online) 2168-4804
    ISSN 2168-4790
    DOI 10.1007/s43441-021-00362-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials.

    Borad, Abhilasha / Saeed, Hamnah / Toscani, Michael / Barone, Joseph / Weber, Paul

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    2020  Volume 26, Issue 6, Page(s) 1475–1481

    Abstract: The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most ...

    Abstract The mean and median ages of diagnosis of multiple myeloma range from 70 to 73 years old, with 63% of patients being over the age of 65. Phase 3 clinical trials are designed to study efficacy in the target disease population and are meant to have the most representative subject pool. The purpose of this review is to identify the age demographic of subjects participating in interventional phase 3 clinical trials that aim to treat multiple myeloma and to determine if they encompass the true age demographic of the disease. To complete this review, a search of phase 3 multiple myeloma research trials with reported results was conducted on clinicaltrials.gov, a national, publicly available resource listing clinical trials. Reported mean or median ages of subjects were identified for each trial, and adjusted averages of these values were calculated. Data from 81 clinical trials were assessed, with 42 trials reporting an average mean age of 65.78 years and 15 trials reporting an average median age of 63.29 years. Based on these results, it was determined that the clinical trials reported in this study enrolled patients that were younger than the true age demographic of the disease. There is an unmet need in research in the older population of patients with multiple myeloma, and this may hinder the generalizability and utility of clinical trial results.
    MeSH term(s) Age Factors ; Aged ; Clinical Trials, Phase III as Topic/statistics & numerical data ; Demography ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy
    Language English
    Publishing date 2020-07-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1330764-2
    ISSN 1477-092X ; 1078-1552
    ISSN (online) 1477-092X
    ISSN 1078-1552
    DOI 10.1177/1078155220934162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top